Aikido Pharma Inc.

Dominari Holdings, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. Its oncology therapeutics includes treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It also creates a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. The company was founded by Gilbert V. Levin and M. Karen Levin in 1967 and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dominari Holdings, Inc. engages in wealth management, investment banking, sales and trading, and asset management through its subsidiaries. It operates through the Dominari Financial and Legacy AIkido business segments. The Dominari Financial segment represents the company’s broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido segment includes Aikido Labs, which manages the investments holdings of the legacy entity. The company was founded by Gilbert V. Levin and M. Karen Levin in 1967 and is headquartered in New York, NY.

NEW YORK , March 3, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today reported an improvement in the manufacturing process for its pancreatic cancer drug, DHA-dFdC, licensed from the University of Texas at Austin. The Company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug.

AIkido Pharma Reports Improved Manufacturing Process and New United States Patent for Pancreatic Drug

NEW YORK, March 2, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company"), today announced the closing of its previously announced registered direct offering with certain institutional investors of 11,000 shares of Series O redeemable convertible preferred stock and 11,000 shares of Series P redeemable convertible preferred stock. Each share of Series O and Series P preferred stock has a purchase price of $952.38, representing an original issue discount of 5% of the $1,000 stated value of each share.

AIkido Pharma Inc. Announces Closing of $22 Million Registered Direct Offering

NEW YORK , Feb. 25, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company"), today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 11,000 shares of Series O redeemable convertible preferred stock and 11,000 shares of Series P redeemable convertible preferred stock.  Each share of Series O and Series P preferred stock has a purchase price of $952.38, representing an original issue discount of 5% of the $1,000 stated value of each share.

AIkido Pharma Inc. Announces $22 Million Registered Direct Offering

NEW YORK , Jan. 24, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI ) ("AIkido" or the "Company"), a clinical and early-stage drug development company, today announced that its board of directors (the "Board") has authorized a share repurchase program to repurchase up to $3 million of the Company's outstanding common stock. The share repurchase authorization is effective immediately.

AIkido Pharma Announces Share Repurchase Program

NEW YORK, Jan. 5, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that Dr. Rachel Yehuda appeared on CBS News discussing the results of a recent FDA-approved trial using a psychedelic drug.  CBS News national security correspondent David Martin talks with a former Marine whose two tours in Iraq presaged twelve years of nightmares, panic attacks and failed relationships – and who now finds hope.

AIkido Pharma Announces Dr. Rachel Yehuda's Appearance on CBS News

BIOLASE

Cinedigm

Which penny stocks are you watching right now? The post Trending Penny Stocks to Watch After Holiday Season appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trending Penny Stocks to Watch After Holiday Season

NEW YORK, Dec. 14, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided a status update on its expansion of key patent applications into several major ex-US territories worldwide. For the Company's pancreatic cancer drug licensed from The University Texas at Austin, in which the Company currently seeks patent protection in the US, the Company will now also seek protection on the licensed drug formulation in China, India and the European Patent Office, with all member countries designated, which includes all 27 EU member countries plus 11 non-EU countries.

AIkido Pharma Reports Filing for Expanded Worldwide Patent Coverage on Key Assets

NEW YORK , Dec. 6, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company secured a strategic equity interest in ASP Isotopes, Inc., which focuses on the non-nuclear supply of enriched isotopes. ASP Isotopes' Aerodynamic Separation Process is a method of enriching molybdenum-100 which is a stable isotope of molybdenum.

AIkido Pharma Announces Strategic Interest in ASP Isotopes Inc.

NEW YORK, Nov. 11, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced its third quarter ending September 30, 2021, financial highlights and provided a corporate update. Highlights Cash and investments exceeding $104 million reflecting very low cash burn over Q2 Monetization and liquidity event in DatChat representing over 600% ROI Investment in Tevva Motors electric truck producer, a space with recent Rivian Automotive IPO, ticker symbol RIVN.

AIkido Pharma Announces Third Quarter Highlights and Corporate Update

Blue Hat Interactive Entertainment Technology

CohBar

Gran Tierra Energy

Oragenics

There are so many traders looking for the best penny stocks 2021… The post 5 Top Penny Stocks To Watch Under $1 After CSCW Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Top Penny Stocks To Watch Under $1 After CSCW Stock Explodes

Luokung Technology Corp

Meten Holding Group Ltd.

If you're making a penny stocks watchlist in November, here's three you should check out The post Best Penny Stocks to Buy Right Now? 3 to Watch This Month appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Right Now? 3 to Watch This Month

Borqs Technologies

Denison Mines

Are these penny stocks on your November watchlist? The post Best Penny Stocks to Buy in November?

Best Penny Stocks to Buy in November? 3 You Need to Know About

9 Meters Biopharma

Progenity

Selecta Biosciences

Trevi Therapeutics Inc

Will these penny stocks meet analysts' expectations? The post 5 Top Penny Stocks Analysts Say To Buy Now With 123%-733% Targets appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Top Penny Stocks Analysts Say To Buy Now With 123%-733% Targets

Photo by Joshua Mayo on Unsplash Biotechnology development company AIkido Pharma Inc. (NASDAQ: AIKI) recently released its 1st-quarter report, which revealed the strongest balance sheet in the company's history with approximately $102 million in cash and cash equivalents.

AIkido Pharma Trading 30% Below Cash Value Despite Positive Indications

Globalstar

Paltalk

October is getting off to a great start for penny stocks, here's three to watch The post Top Penny Stocks to Watch As October Gets Off to a Bullish Start appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Watch As October Gets Off to a Bullish Start

Nxt-ID

Superior Drilling Products

Best penny stocks to watch under $1? The post 5 Penny Stocks To Watch Under $1 After CEI Stock's 900% Rally appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Watch Under $1 After CEI Stock's 900% Rally

NEW YORK, Sept. 28, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company secured an equity interest in Tevva Motors Ltd, an electric truck producer with range extended vehicles on the road now.

AIkido Pharma Secures Interest in Electric Truck Maker, Tevva Motors Ltd

Clovis Oncology

Viveve Medical

Biotech penny stocks are heating up right now, here's three to watch The post Are Biotech Penny Stocks Worth Buying? Check These 3 Out appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Are Biotech Penny Stocks Worth Buying? Check These 3 Out

NEW YORK, Sept. 20, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company secured an early equity interest in tele-health company, Kerna Health (https://kernahealth.com).

AIkido Pharma Secures Interest in Growing Tele-health Company

NEW YORK, Sept. 14, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today released the following shareholder update: Dear Shareholder, September is an opportune time to provide a shareholder and investor update and we are pleased to report on positive developments and near-term upcoming potential value creating catalysts.

AIkido Pharma Releases Shareholder Update; Near Term Catalysts Approaching

NEW YORK, Aug. 6, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided and update on the use of Machine Learning in support of its antiviral platform with the University of Maryland Baltimore School of Medicine.  The Company stated:  The goal for the project is the identification and optimization of anti-viral compounds that inhibit viral replication by targeting a protein complex that degrades RNA at the cellular level.

AIkido Provides Update on Use of Machine Learning in Drug Development Program

NEW YORK, July 27, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for application No.: 16/477,125.

Notice of Allowance Issued for Central Nervous System Peptide Technology

NEW YORK, July 16, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update to the progress of its antiviral platform with the University of Maryland School of Medicine.  The Company stated: The goal for the project is the identification and optimization of anti-viral compounds that inhibit viral replication by targeting a protein complex that degrades RNA at the cellular level.

AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland

NEW YORK, July 13, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced it will attend the Alzheimer's Association International Conference in Denver, July 26-30, 2021. ("AAIC 2021") The AAIC is the largest and most influential international meeting dedicated to advancing dementia science.

AIkido Pharma to Attend the Alzheimer's Association International Conference

NEW YORK, June 23, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company has filed a provisional patent application for the use of ketamine and peptides to treat Alzheimer's disease.  The Company previously secured and announced the acquisition of patent rights for use of peptides as a drug delivery system.

News for Aikido Pharma Inc. Stock (AIKI)